Association study of -1727 A/T, -50 C/T and (CAA)n repeat GSK-3β gene polymorphisms with schizophrenia

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Glycogen synthase kinase-3 (GSK-3) is a downstream component of the Wnt pathway and recent studies have reported abnormal levels of GSK-3β in schizophrenia. In a sample of 147 schizophrenic patients and 212 healthy individuals, we analyzed two common SNPs at position -1727 A/T and -50 C/T and a (CAA)n repeat polymorphism localized in intron 1 of the gene. The results showed that the allele, genotype and haplotype distributions for the three polymorphisms investigated do not differ between schizophrenic patients in general and control subjects. However, in the subtype of paranoid schizophrenic patients, we found that the (CAA)3/(CAA)5 heterozygotes were more often represented. Although taken from a small sample, our results support the reports that GSK-3β appears to be involved in a subtype of schizophrenic patients, but not in schizophrenia in general. In conclusion, we would speculate that this gene may be linked to some features of psychotic disorders rather than to schizophrenia itself.

Original languageEnglish
Pages (from-to)16-20
Number of pages5
JournalNeuropsychobiology
Volume50
Issue number1
DOIs
Publication statusPublished - 2004

Fingerprint

Glycogen Synthase Kinase 3
Schizophrenia
Genes
Wnt Signaling Pathway
Heterozygote
Psychotic Disorders
Introns
Haplotypes
Single Nucleotide Polymorphism
Alleles
Genotype

Keywords

  • Glycogen synthase kinase-3β (GSK-3β)
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)
  • Psychology(all)

Cite this

@article{77a373f042ff4d4abd9cd6c711d888f8,
title = "Association study of -1727 A/T, -50 C/T and (CAA)n repeat GSK-3β gene polymorphisms with schizophrenia",
abstract = "Glycogen synthase kinase-3 (GSK-3) is a downstream component of the Wnt pathway and recent studies have reported abnormal levels of GSK-3β in schizophrenia. In a sample of 147 schizophrenic patients and 212 healthy individuals, we analyzed two common SNPs at position -1727 A/T and -50 C/T and a (CAA)n repeat polymorphism localized in intron 1 of the gene. The results showed that the allele, genotype and haplotype distributions for the three polymorphisms investigated do not differ between schizophrenic patients in general and control subjects. However, in the subtype of paranoid schizophrenic patients, we found that the (CAA)3/(CAA)5 heterozygotes were more often represented. Although taken from a small sample, our results support the reports that GSK-3β appears to be involved in a subtype of schizophrenic patients, but not in schizophrenia in general. In conclusion, we would speculate that this gene may be linked to some features of psychotic disorders rather than to schizophrenia itself.",
keywords = "Glycogen synthase kinase-3β (GSK-3β), Schizophrenia",
author = "Catia Scassellati and Cristian Bonvicini and Jorge Perez and Luisella Bocchio-Chiavetto and Tura, {Gian Battista} and Giuseppe Rossi and Giorgio Racagni and Massimo Gennarelli",
year = "2004",
doi = "10.1159/000077936",
language = "English",
volume = "50",
pages = "16--20",
journal = "Neuropsychobiology",
issn = "0302-282X",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Association study of -1727 A/T, -50 C/T and (CAA)n repeat GSK-3β gene polymorphisms with schizophrenia

AU - Scassellati, Catia

AU - Bonvicini, Cristian

AU - Perez, Jorge

AU - Bocchio-Chiavetto, Luisella

AU - Tura, Gian Battista

AU - Rossi, Giuseppe

AU - Racagni, Giorgio

AU - Gennarelli, Massimo

PY - 2004

Y1 - 2004

N2 - Glycogen synthase kinase-3 (GSK-3) is a downstream component of the Wnt pathway and recent studies have reported abnormal levels of GSK-3β in schizophrenia. In a sample of 147 schizophrenic patients and 212 healthy individuals, we analyzed two common SNPs at position -1727 A/T and -50 C/T and a (CAA)n repeat polymorphism localized in intron 1 of the gene. The results showed that the allele, genotype and haplotype distributions for the three polymorphisms investigated do not differ between schizophrenic patients in general and control subjects. However, in the subtype of paranoid schizophrenic patients, we found that the (CAA)3/(CAA)5 heterozygotes were more often represented. Although taken from a small sample, our results support the reports that GSK-3β appears to be involved in a subtype of schizophrenic patients, but not in schizophrenia in general. In conclusion, we would speculate that this gene may be linked to some features of psychotic disorders rather than to schizophrenia itself.

AB - Glycogen synthase kinase-3 (GSK-3) is a downstream component of the Wnt pathway and recent studies have reported abnormal levels of GSK-3β in schizophrenia. In a sample of 147 schizophrenic patients and 212 healthy individuals, we analyzed two common SNPs at position -1727 A/T and -50 C/T and a (CAA)n repeat polymorphism localized in intron 1 of the gene. The results showed that the allele, genotype and haplotype distributions for the three polymorphisms investigated do not differ between schizophrenic patients in general and control subjects. However, in the subtype of paranoid schizophrenic patients, we found that the (CAA)3/(CAA)5 heterozygotes were more often represented. Although taken from a small sample, our results support the reports that GSK-3β appears to be involved in a subtype of schizophrenic patients, but not in schizophrenia in general. In conclusion, we would speculate that this gene may be linked to some features of psychotic disorders rather than to schizophrenia itself.

KW - Glycogen synthase kinase-3β (GSK-3β)

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=2642543937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2642543937&partnerID=8YFLogxK

U2 - 10.1159/000077936

DO - 10.1159/000077936

M3 - Article

C2 - 15179015

AN - SCOPUS:2642543937

VL - 50

SP - 16

EP - 20

JO - Neuropsychobiology

JF - Neuropsychobiology

SN - 0302-282X

IS - 1

ER -